$CPRX

Thompson Tamar sold (to issuer) $119K of CPRX

Thompson Tamar sold (to issuer) 3,773 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($0.12M total) on 2026-07-15.

Original reporting
SEC EDGAR · Thompson Tamar
Published Jul 17, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CPRX
Neutral
medium confidence
Mentioned
$CPRX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CPRXNeutralLow
01

Why it matters

The newest disclosed fact is the director’s sale of 3,773 shares at $31.50/share, with holdings after the transaction reported as 0 shares.

02

Market read

Traders may note insider selling and the transaction price, but there is no accompanying fundamental catalyst in the text.

03

What to watch

No 10b5-1 plan is indicated, but the filing does not explain intent; without additional insider activity or fundamental news, signal quality is low.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-17 for a sale dated 2026-07-15 (after-hours filing window).

Background

The filing is an SEC Form 4 insider transaction for Catalyst Pharmaceuticals, Inc. (CPRX).

Company-level read

Ticker impact

$CPRXNeutralMedium confidence
Context

Catalyst Pharmaceuticals director Thompson Tamar sold 3,773 shares to the issuer on 2026-07-15 at $31.50/share, leaving 0 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only unless paired with other disclosures.

Evidence & confidence

Form 4 provides a concrete transaction and price, but it does not include new company fundamentals, guidance, or regulatory/operational developments.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale is coded as “sale to issuer” and may reflect scheduled buyback participation or liquidity needs rather than bearish information.

Key entities

  • CATALYST PHARMACEUTICALS, INC.

    CPRX, the company whose director insider transaction is disclosed.

  • Thompson Tamar

    Director who sold 3,773 shares to the issuer on 2026-07-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles